LifeStance Health Group, Inc.

Valuation Analysis

About the Company

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is

LifeStance Health Group, Inc. Stock at a Glance

LifeStance Health Group, Inc. (LFST) is currently trading at $8.50 with a market capitalization of $3.2B. The trailing P/E ratio stands at 141.67x, with a forward P/E of 21.68x. The 52-week range spans from $3.74 to $8.89; the current price is 4.4% below the yearly high. Year-over-year revenue growth stands at +21.2%. The net profit margin stands at 1.55%.

💰 Dividend

LifeStance Health Group, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

10 analysts rate LifeStance Health Group, Inc. (LFST) on consensus: Buy. The average price target is $10.55, implying +24.12% from the current price. Analyst price targets range from $9.00 to $13.00.

LifeStance Health Group, Inc.: The Investment Case in Detail

LifeStance Health Group, Inc. (LFST) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 21.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 1927.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 24.12% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

With a net margin of just 1.55%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The EV/EBITDA multiple of 35.7x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 21.68x is meaningfully below the trailing 141.67x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 92.4% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
• The analyst consensus price target implies 24.12% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy LifeStance Health Group, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.